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Abstract
A common mutation of the epidermal growth factor receptor (EGFR) in glioblastoma multiforme (GBM) is an extra-
cellular truncation known as the de2-7 EGFR (or EGFRvIII). Hepatocyte growth factor (HGF) is the ligand for the recep-
tor tyrosine kinase (RTK) c-Met, and this signaling axis is often active in GBM. The expression of the HGF/c-Met axis
or de2-7 EGFR independently enhances GBMgrowth and invasiveness, particularly through the phosphatidylinositol-3
kinase/pAkt pathway. Using RTK arrays, we show that expression of de2-7 EGFR in U87MG GBM cells leads to the
coactivation of several RTKs, including platelet-derived growth factor receptor β and c-Met. A neutralizing antibody
toHGF (AMG102) did not inhibit de2-7EGFR–mediated activationof c-Met, demonstrating that it is ligand-independent.
Therapy for parental U87MG xenografts with AMG 102 resulted in significant inhibition of tumor growth, whereas
U87MG.Δ2-7 xenografts were profoundly resistant. Treatment of U87MG.Δ2-7 xenografts with panitumumab, an
anti-EGFR antibody, only partially inhibited tumor growth as xenografts rapidly reverted to the HGF/c-Met signaling
pathway. Cotreatment with panitumumab and AMG 102 prevented this escape leading to significant tumor inhibition
through an apoptotic mechanism, consistent with the induction of oncogenic shock. This observation provides a
rationale for using panitumumab and AMG 102 in combination for the treatment of GBM patients. These results illus-
trate that GBM cells can rapidly change the RTK driving their oncogene addiction if the alternate RTK signals through
the same downstream pathway. Consequently, inhibition of a dominant oncogene by targeted therapy can alter the
hierarchy of RTKs resulting in rapid therapeutic resistance.
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Introduction
The most common malignant neoplasm of the brain is glioblastoma
multiforme (GBM), accounting for approximately 25% of brain
tumors [1]. GBM is among the most lethal and difficult forms of cancer
to treat; thus, the development of novel therapeutic options is critical
[1]. At least three key signaling pathways seem to be associated with
the development of GBM: the p53, the retinoblastoma protein, and
receptor tyrosine kinase (RTK)/ras/phosphatidylinositol-3 kinase path-
ways [2,3]. Activation of phosphatidylinositol-3 kinase is often medi-
ated by signaling from the epidermal growth factor receptor (EGFR)
and/or c-Met RTKs [2].
The EGFR has been shown to be activated in GBM by autocrine
loop, overexpression, gene amplification, missense mutation, and mul-
tiple exon deletion [4–11]. A recent comprehensive analysis of the
EGFR demonstrated that, collectively, alterations of the EGFR occur
in 45% of GBM patients [2]. Including overexpression and functional
Abbreviations: EGFR, epidermal growth factor receptor; GBM, glioblastoma multi-
forme; HGF, hepatocyte growth factor; PDGFRβ, platelet-derived growth factor re-
ceptor β; RTK, receptor tyrosine kinase
Address all correspondence to: Terrance G. Johns, Monash Medical Centre, Monash
Institute of Medical Research, 246 Clayton Rd, Clayton 3168 Victoria, Australia.
E-mail: Terry.Johns@med.monash.edu.au
1This grant was funded in part by theNationalHealth&Medical Council of Australia (Proj-
ect Grant 433615) and the James S. McDonnell Foundation Research (no. 220020173).
2This article refers to supplementary materials, which are designated by Figures W1
and W2 and are available online at www.neoplasia.com.
Received 24 January 2009; Revised 20 February 2009; Accepted 22 February 2009
Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00
DOI 10.1593/neo.09230
www.neoplasia.com
Volume 11 Number 5 May 2009 pp. 448–458 448
autocrine loops in this figure, it is clear that most patients have some
activation of the EGFR, supporting a fundamental role for this recep-
tor in the development and progression of GBM. Numerous studies
have shown that the most common mutation in GBM is the de2-7
EGFR, occurring in approximately 50% of cases where the EGFR gene
is amplified [8,10]. However, this estimate might be on the low side
because some GBMs only have a low percentage of cells expressing
the de2-7 EGFR making it difficult to detect [6]. This cancer-specific
EGFR mutant has a complete deletion of exons 2 to 7 of EGFR. The
truncation leads to the elimination of 267 amino acids from the ex-
tracellular domain and the insertion of a novel glycine at the fusion
junction. This renders the mutant EGFR unable to bind any known
ligand. Despite this, the de2-7 EGFR is capable of low-level constitu-
tive signaling, which is augmented by the mutant receptor’s impaired
internalization and down-regulation [12].
The MET gene, which encodes the c-Met RTK, is amplified in
approximately 4% of GBMs but is only rarely mutated [2]. However,
coexpressions of c-Met with its ligand, scatter factor/hepatocyte
growth factor (HGF), is often seen in GBM, and this has been shown
to correlate with tumor grade [13]. Furthermore, transfection of GBM
cells with HGF enhances their tumorigenicity and growth, and the
inhibition of HGF or c-Met in vivo inhibits tumor formation and
cell growth, all indicating that this signaling axis has a key role in this
tumor [14,15]. Expression of HGF may also have an indirect role in
tumor development through stimulation of angiogenesis, predomi-
nantly by activation of vascular endothelial cells [14,15].
Oncogenic addiction is the proposed mechanism by which a tumor
cell becomes largely reliant on a single activated oncogene [16,17]. It
has also been suggested that oncogene addiction leads to activation of
both survival and apoptotic pathways, but in viable tumor cells, the
prosurvival signal outweighs the apoptotic signal [18]. Sudden inhibi-
tion of this dominant oncogenic signal can lead to oncogenic shock, a
scenario where, after withdrawal of the signal, mediators of survival
decay faster than those associated with apoptosis, resulting in an excess
of proapoptotic signals and cell death [18]. Given their apparent domi-
nant role in some GBM, targeted therapies that inhibit the function of
EGFR or c-Met may have antitumor activity in this disease through
this mechanism [19,20]. Two such targeted therapies are AMG 102, a
fully human antibody directed to HGF/scatter factor currently under-
going clinical evaluation in GBM [21], and panitumumab, a clinically
approved fully human antibody directed to the EGFR [22].
The GBM cell line, U87MG, contains a robust c-Met/HGF auto-
crine loop that strongly drives its proliferation and survival [21].
Therapeutics directed to either HGF or c-Met inhibit the growth
of U87MG cells in vitro and possess antitumor activity against
U87MG xenografts [21,23]. Very recently, it was suggested that
the de2-7 EGFR leads to increased phosphorylation of c-Met when
coexpressed in U87MG cells [24]. Given this potential interplay be-
tween de2-7 EGFR and c-Met, we sought to determine what effect
de2-7 EGFR expression has on AMG 102 therapy. Furthermore, we
examined the antitumor activity of AMG 102 in combination with
panitumumab. Finally, we determined whether the expression of
de2-7 EGFR activates other RTKs in GBM cells.
Materials and Methods
Cell Lines and Monoclonal Antibodies
A549 cells were obtained from American Type Tissue Collection
(Manassas, VA). The U87MG parental cells and its transfected variants,
U87MG.Δ2-7, U87MG.DK, and U87MG.DY5, have been described
in detail previously [25]. To ensure the quality of our U87MG-derived
cell lines, we routinely produce new transfected cell lines. To guarantee
the original characteristics of the parental line are retained, apart from
expression of the de2-7 EGFR, cells are not cloned but sorted for the
top 10% of de2-7 EGFR–expressing cells. Further precautions include
discarding cells after 8 to 12 weeks in culture, always using early-passage
freeze downs, and transfection controls. All cell lines were maintained
in Dulbecco’s modified Eagle’s medium/F12 containing 10% fetal calf
serum, 2 mM glutamine, and penicillin/streptomycin (Invitrogen,
Melbourne, Victoria, Australia). In addition, transfected cell lines were
maintained in 400 μg/ml Geneticin (Invitrogen). AMG 102 and pani-
tumumab were provided by Amgen, Inc (Thousand Oaks, CA).
Human Phospho-RTK Arrays
Cells were seeded in complete medium, allowed to attach over-
night, and then serum-starved for 18 to 20 hours. The cells were
harvested with 0.05% EDTA prepared in PBS, washed twice with
ice-cold PBS, and counted. Cells (∼1.2 × 107 per treatment) were then
lysed and analyzed with human Phospho-RTK arrays (R&D Systems,
Minneapolis, MN) as per manufacturer’s instructions.
Western Blot Analyses
For the detection of total and phosphorylated c-Met, cells were
seeded at a density of 120,000 to 150,000 cells per well in a six-well
cell culture plate and were allowed to attach overnight. Cells were
washed twice with PBS and once with serum-free medium and then
serum-starved in the presence and absence of antibody treatments.
Cells were washed twice with ice-cold PBS and lysed by adding
Triton X-100 cell lysis buffer [30 mM HEPES, pH 7.4, 150 mM
NaCl, 1% Triton X-100, 10 mM NaF, Calbiochem Protease Inhibi-
tor Cocktail Set I, 200 μM Na3VO4, and 0.4% (v/v) H2O2] and
incubating on ice for 20 minutes. The lysates were then clarified by
centrifugation at 4°C before immunoprecipitation of c-Met was con-
ducted using the anti–c-Met (C-28) antibody conjugated to agarose
beads (Santa Cruz Biotechnology, Santa Cruz, CA).
For the detection of total and phosphorylated de2-7 EGFR, cells
were seeded and treated as described above, harvested with trypsin,
and washed twice with PBS. Cells were then lysed by resuspending
the cell pellet in RIPA buffer [50 mM HEPES, pH 7.4, 150 mM
NaCl, 10% (v/v) glycerol, 5 mM EDTA, 1% (v/v) Triton X-100,
1% (v/v) sodium deoxycholate, 0.1% (v/v) SDS, 10 mM NaF, Cal-
biochem Protease Inhibitor Cocktail Set I, 200 μM Na3VO4, and
0.4% (v/v) H2O2] and incubated on ice for 5 to 10 minutes. The lysate
was clarified by centrifugation at 4°C.
Protein samples were separated on NuPAGE Novex 4% to 12%
Bis-Tris Gels (Invitrogen) and transferred to polyvinylidene difluoride
membranes using the iBlot Dry Blotting System (Invitrogen). All
blocking steps and antibody incubations were performed in Odyssey
Blocking Buffer (LI-COR Biosciences, Lincoln, NE). Total c-Met and
phosphorylated c-Met was detected by probing with Met (25H2)
mouse mAb (Cell Signaling Technology, Danvers, MA) and rabbit
(polyclonal) phosphospecific anti–c-Met [pYpYpY1230/1234/1235]
(Invitrogen), respectively. Total EGFR was detected by probing with
mAb 806 (produced in the Biological Production Facility, Ludwig Insti-
tute for Cancer Research, Melbourne, Australia), and phosphorylated
EGFR was detected with phospho-EGFR (Tyr1173) (53A5) rabbit
mAb and phospho-EGFR (Tyr1068) antibody (Cell Signaling Technol-
ogy).α-Tubulinwas detected by probingwithα-tubulin (B-7; SantaCruz
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Biotechnology). Secondary antibodies used for detection were either
IRDye 800CW–conjugated affinity-purified antirabbit immunoglobulin
G (IgG; H&L; Rockland Immunochemicals, Gilbertsville, PA) or Alexa
Fluor 680 goat antimouse IgG (H+L; Invitrogen).Western blots were an-
alyzed with the Odyssey Infrared Imaging System (LI-COR Biosciences).
Bio-Plex Assays
Cells were seeded at a density of 200,000 cells per well in six-well
cell culture plates and allowed to attach overnight. Cells were washed
twice with PBS and once with serum-free medium and then serum-
starved in the presence and absence of antibody treatments. The cells
were then washed and lysed, and the lysates were analyzed for levels of
phosphorylated platelet-derived growth factor receptor β (PDGFRβ) or
Akt using the Bio-Plex Phosphoprotein Detection Reagent Kit, Bio-
Plex Cell Lysis Kit, Bio-Plex Phosphoprotein Assays (PDGFRβ and
Akt), and Bio-Plex Total Target Assays (Akt; Bio-Rad Laboratories,
Hercules, CA) according to the manufacturer’s protocol.
Xenograft Models
Tumor cells (2 × 106) in 100 μl of growth medium were inoculated
subcutaneously into both flanks of 4- to 6-week-old, female BALB/c
nude mice (Animal Research Centre, Perth, Australia). All studies were
conducted using established tumor models as previously reported [25].
Treatment commenced once tumors had reached a mean volume of 80
to 130 mm3 and was administered by intraperitoneal (i.p.) injection.
Tumor volume in cubic millimeters was determined using the formula
(length × width2) / 2, where length was the longest axis and width was
the measurement at right angles to the length. Data are expressed as
mean tumor volume ± SEM for each treatment group. All data were
analyzed for significance by Student’s t test. This research project was
approved by the Animal Ethics Committee of the Austin Hospital.
Immunohistochemistry
Blood vessels were identified using monoclonal rat antimouse
CD31 (5 μg/ml; BD Biosciences Pharmingen, San Jose, CA). Prolifer-
ating cells were identified using monoclonal rabbit antimouse Ki67
(1:100 supernatant; Neomarkers, Freemont, CA). Apoptotic cells were
identified with a terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling–peroxidase (TUNEL-POD) in situ cell death
detection kit (Roche Diagnostics, Mannheim, Germany).
For CD31 and Ki67 analysis, frozen sections (6 μm) were fixed in
acetone for 5 minutes and washed in PBS for 30 minutes. Sections
were incubated with 3% H2O2 in methanol for 10 minutes to quench
endogenous peroxidase. All sections were incubated with a protein-
blocking solution (Dako Australia, Kingsgrove, Australia) to prevent
nonspecific binding. Negative controls were performed by replacing
the primary antibodies with an isotype-matched IgG control at the
same concentration as the primary antibody. The TUNEL-POD was
performed according to the manufacturer’s instructions. A TUNEL-
POD–negative control was prepared by the removal of the primary
antibody, whereas the positive control was prepared by incubating sec-
tions with a DNAse/Tris solution according to the manufacturer’s in-
structions (10 minutes at 24°C) before incubating with the primary
antibody. In all cases, incubation with primary antibody was 1 hour at
room temperature.
Anti-CD31 was visualized with an antirat biotinylated antibody
for 1 hour (1:200; Invitrogen) followed by LSAB-2 HRP (15 min;
Dako Australia) and color development with the chromogen 3,30-
diaminobenzidine (Sigma Aldrich, St. Louis, MO). Anti-Ki67 was
visualized with Envision antirabbit–HRP (30 minutes; Dako Australia)
followed by aminoethyl carbazole (Invitrogen). The TUNEL immu-
nostains were incubated with the POD converter antibody (1 hour
at 37°C) and visualized with 3,30-diaminobenzidine.
All image analyses were performed using the Analytical Imaging
System (AIS 30, Rev 1.7; Imaging Research Inc. GE Healthcare Bio-
Sciences, Rydalmere, NSW, Australia). Positive cells or vessels were
counted from six fields of view, results were presented as mean values
± SEM, and statistical tests were performed using the Statistical Package
for the Social Sciences for Windows, version 15.1 (SPSS, Inc, Chicago,
IL). Data were analyzed using one-way analysis of variance followed
by Tukey’s post hoc tests and Student’s t test for individual mean analysis.
P < .05 was considered significant.
Results
Coactivation of RTKs in Glioma Cells Expressing the
de2-7 EGFR
To identify cell surface RTKs potentially activated by the de2-7
EGFR, whole-cell lysates from U87MG.Δ2-7 and U87MG.DK cell
lines were analyzed using a human phospho-RTK antibody array.
Multiple RTKs were shown to be coactivated in U87MG.Δ2-7 gli-
oma cells expressing the constitutively active de2-7 EGFR compared
with U87MG.DK cells expressing the kinase dead de2-7 EGFR
(Figure 1A), including c-Met, PDGFRβ, vascular endothelial growth
factor receptor 3, EphA7, fibroblast growth factor receptor 3, and Axl.
This coactivation observed by antibody array was confirmed for two of
the RTKs: c-Met by Western blot (Figure 1B) and PDGFRβ by Bio-
Plex (Figure 1C). We repeated the array experiment with an indepen-
dent U87MG.Δ2-7 cell line derived earlier and obtained near-identical
results. Thus, expression of the de2-7 EGFR leads to activation of sev-
eral cell surface RTKs.
Effect of Inhibiting the de2-7 EGFR on Activation of
RTKs and Akt
To determine the effect of panitumumab (an anti-EGFR antibody) on
de2-7 EGFR activation, the receptor from U87MG.Δ2-7 cells treated
with this antibody was analyzed for its phosphorylation status at two
of the major autophosphorylation sites (Y1086 and Y1173). The
level of phosphorylation at Y1086 and Y1173 was greatly reduced with
panitumumab treatment, indicating that this antibody inhibits phos-
phorylation of the de2-7 EGFR (Figure 2A). Analysis of total receptor
levels showed that panitumumab partially downregulated the receptor,
although the effect was smaller than that seen on phosphorylation. These
findings demonstrate that panitumumab inhibits the de2-7 EGFR.
Given that a recent study has shown that the de2-7 EGFR drives
ligand-independent phosphorylation of c-Met [24], the effect of
AMG 102 (a neutralizing anti-HGF antibody) or panitumumab
on c-Met phosphorylation was examined by Western blot analysis. Fig-
ure 2B shows that c-Met is robustly phosphorylated in U87MG.Δ2-7
cells even in the presence of AMG 102. In contrast, treatment of
U87MG.Δ2-7 cells with panitumumab resulted in a profound decrease
in c-Met phosphorylation (Figure 2B). As expected, combination treat-
ment with panitumumab and AMG 102 also fully inhibited the phos-
phorylation of c-Met. Thus, activated de2-7 EGFR drives c-Met
phosphorylation in an HGF-independent fashion.
The effect of panitumumab on another de2-7 EGFR–activated RTK,
PDGFRβ, was also tested. Lysates from untreated U87MG.Δ2-7 cells,
as well as cells treated with AMG 102, panitumumab, or a combination
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of both, were analyzed by Bio-Plex to determine the degree of phos-
phorylation of PDGFRβ. Treatment with AMG 102 yielded only a
small reduction in PDGFRβ phosphorylation, whereas treatment with
panitumumab resulted in a profound decrease in PDGFRβ phosphor-
ylation (Figure 2C ). Combination treatment with panitumumab and
AMG 102 had resulted in inhibition similar to panitumumab alone.
Therefore, de2-7 EGFR also mediates phosphorylation of PDGFRβ.
The effect of panitumumab and AMG 102 on activation of Akt, a
major downstream target of the EGFR and c-Met signaling pathways,
was examined using Bio-Plex [26]. Treatment of U87MG.Δ2-7 cells
with AMG 102 caused no reduction in Akt phosphorylation (pAkt),
whereas treatment with panitumumab resulted in complete inhibition
of pAkt (Figure 2D). Not surprisingly, combination treatment with
panitumumab and AMG 102 also completely inhibited pAkt (Fig-
ure 2D). As anticipated, U87MG.DK cells had much lower levels of
basal pAkt (cf., the scales in Figure 2E with Figure 2D) because of
the absence of a functional de2-7 EGFR. Treatment of U87MG.
DK cells with AMG 102 yielded a substantial decrease in pAkt
(Figure 2E ), demonstrating that AMG 102 does inhibit c-Met sig-
naling in U87MG-derived cells lacking a functional de2-7 EGFR.
Treatment of U87MG.DK cells with panitumumab reduced pAkt
compared with untreated cells (Figure 2E ), suggesting that at least
some of the pAkt is generated by the wild-type EGFR that is co-
expressed in these cells. Combination treatment with both antibodies
did not have any additional effects on pAkt compared with AMG 102
treatment alone (Figure 2E). The levels of total Akt in the U87MG.Δ2-7
cells were not significantly changed by any of the antibody treatments
(Figure 2F ); however, panitumumab alone and in combination with
AMG 102 reduced the level of total Akt in U87MG.DK cells (Fig-
ure 2G ). This reduction was less than the reduction in pAkt. Thus,
AMG 102 is unable to inhibit pathways downstream of c-Met when
de2-7 EGFR is coexpressed.
Treatment of Established Glioma Xenografts with
Panitumumab and AMG 102
U87MG and U87MG.Δ2-7 glioblastoma xenografts were treated
with AMG 102 to determine whether the de2-7 EGFR reduces efficacy
of AMG 102 treatment. Treatment of established U87MG xenografts
with 30 μg of AMG 102, twice a week for 2 weeks, produced a signifi-
cant antitumor response (Figures 3A and W1). The average tumor vol-
umes on day 49 after inoculation were 1580 and 260 mm3 (P < .0001)
for the vehicle and AMG 102 treatment groups, respectively. Two of
the 16 tumors in the AMG 102 group showed complete regression;
histological examination of two other tumors that had regressed showed
only small clusters of remaining tumor cells. In contrast, U87MG.Δ2-7
xenografts were relatively resistant to AMG 102 therapy (Figure 3B).
The average tumor volumes on day 19 after inoculation were 1820
and 1360 mm3 (P = .02) for the vehicle and AMG 102 treatment
groups, respectively. This result indicates that the expression of de2-7
EGFR causes significant resistance toAMG102.U87MG.wt xenografts,
which overexpress the wild-type EGFR to a similar level as de2-7 EGFR
inU87MG.Δ2-7 cells, were treatedwithAMG102 to determinewhether
this receptor also influences the efficacy of AMG 102. Treatment of
established U87MG.wt xenografts with AMG 102 produced a sig-
nificant antitumor response comparable to that observed in the par-
ental xenografts (Figure 3C ). The average tumor volumes on day 47
after inoculation were 1400 and 250 mm3 (P < .0001) for the vehicle
and AMG 102 treatment groups, respectively. This result indicates that
overexpression of the wild-type EGFR does not mediate resistance
to AMG 102.
U87MG.Δ2-7 xenografts were then treated with a combination of
panitumumab and AMG 102 and each of the antibodies alone to de-
termine whether panitumumab reverses the resistance mediated by the
de2-7 EGFR (Figures 3D and W1). Tumors in all three antibody-
treated groups were significantly smaller than in the vehicle-treated
Figure 1. Coactivation of RTKs by de2-7 EGFR in U87MG cell lines. (A) RTK antibody arrays were used to compare RTK activation in
glioma cells expressing the de2-7 EGFR (U87MG.Δ2-7) or dead kinase de2-7 EGFR (U87MG.DK). The identity of phosphorylated RTKs is
indicated by number. (B) Western blot analysis showing levels of phosphorylated and total c-Met in U87MG cells (lane 1), U87MG cells
stimulated with HGF (lane 2), U87MG.Δ2-7 cells (lane 3), and U87MG.DK cells (lane 4). (C) Comparison of phosphorylated PDGFRβ in
U87MG.Δ2-7 and U87MG.DK cell lines as determined by Bio-Plex assay. All assays performed a minimum of three times.
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group at day 19 after inoculation. The mean tumor volumes were
1820, 1360, 570, and 170 mm3 for the vehicle, AMG 102 (P = .02),
panitumumab (P < .0001), and combination (P < .0001) treatment
groups, respectively (Figure 3D). The combination of panitumumab
and AMG 102 resulted in the greatest antitumor activity and was sig-
nificantly more efficacious than the panitumumab-alone group (P =
.0008 at day 26 after inoculation). Thus, panitumumab reversed
the resistance to AMG 102 mediated by the de2-7 EGFR resulting in
greater than additive antitumor activity.
To determine whether the resistance of U87MG.Δ2-7 xenografts to
AMG 102 could be overcome by using a higher dose of the antibody,
we repeated the above experiment using a dose of 100 μg of AMG 102
twice a week for 2 weeks (Figure 3E). The average tumor volumes on
day 21 after inoculation were 2150, 1530, 780, and 150 mm3 for the
vehicle, AMG 102, panitumumab, and combination treatment
groups, respectively (Figure 3E). Treatment with the higher dose of
AMG 102 resulted in a small inhibition of tumor growth (P = .03),
but it failed to overcome the resistance mediated by the de2-7 EGFR.
Once again, the combination of high-dose AMG 102 with panitumu-
mab was more effective than either agent alone; however, the antitumor
activity was similar to that seen at the lower dose of AMG 102 (cf.,
Figure 3D).
Mechanism of Antitumor Activity
To elucidate the antitumor mechanisms of panitumumab and
AMG 102, we conducted an immunohistochemical analysis on
U87MG.Δ2-7 xenografts harvested from mice killed mid treatment
(1 day after the second injection). This time point was chosen to de-
termine the primary effects of treatment. Mice were treated with
vehicle, AMG 102, panitumumab, or the combination of these
two antibodies as described above for Figure 3D. To determine whether
antibody treatment had an antiproliferative effect on xenografts, we
analyzed the number of Ki67-positive cells, a marker for proliferating
cells. There was no significant difference in the number of Ki67-positive
cells per field of view (P = .201) among the treatment groups (Figure 4,
A and B).
The microvessel density of treated U87MG.Δ2-7 xenografts was
assessed by immunostaining sections for CD31 (Figure 4, C and D).
The average number of CD31-positive microvessels per field of view
was 47, 42, 33, and 42 for the vehicle, panitumumab, AMG 102,
and combination treatment groups, respectively. The AMG 102 treat-
ment group had significantly fewer CD31-positive vessels compared
with the other groups (P = .004), indicating that AMG 102 treatment
was able to restrict intratumoral vasculature development. Treatment
with panitumumab alone or in combination with AMG 102 had no
effect on tumor vessel density.
The effect of antibody treatment on tumor apoptosis was exam-
ined in U87MG.Δ2-7 xenografts using the TUNEL-POD method.
The average number of cells staining positive for TUNEL per field
of view was 0.5, 19, 1, and 30 for the vehicle, panitumumab, AMG
102, and combination treatment groups, respectively (Figure 4, E
and F ). Both the panitumumab and combination therapy groups
showed a significant increase in apoptosis compared with vehicle-
treated xenografts (P = .047 and P = .012, respectively). Apoptosis in
the combination group was higher than that in the panitumumab
group, but this did not reach statistical significance (P = .29). However,
this result was based on the analysis of the whole tumor section and,
therefore, may be an underestimate of the difference between the two
groups because the enhancement of apoptosis seen in the combination
therapy group was mostly restricted to the central regions of the tumor
(Figure 4F ). We were unable to stain sections for phospho–c-Met be-
cause all three antibodies used showed cross-reactivity with the de2-7
EGFR (Figure W2).
Role of de2-7 EGFR Autophosphorylation in Resistance
to AMG 102 Therapy
To further assess the mechanism by which de2-7 EGFR interacts
with c-Met and causes resistance to AMG 102, we treated animals
bearing U87MG.DY5 xenograft tumors with this antibody. This
DY5 version of the de2-7 EGFR is unable to autophosphorylate at
the five major autophosphorylation sites associated with signaling
(Y1173, Y1148, Y1086, Y1068, and Y992 have been changed to phe-
nylalanine) but retains an active kinase domain. Figure 5A confirms
this lack of phosphorylation at two of the major sites, Y1068 and
Y1173. Whereas U87MG.DY5 xenografts grew more slowly than
U87MG.Δ2-7 xenografts, the difference was smaller than previously
reported. Earlier studies were conducted using intracranial tumors ini-
tiated by a low cell number (5 × 103). Current xenografts were grown
subcutaneously using considerably more cells (2 × 106); both of these
changes partially mask the growth advantage of the de2-7 EGFR.
Treatment of established U87MG.DY5 xenografts with 30 μg of
AMG 102, twice a week for 2 weeks, yielded no response to AMG
102 therapy compared with treatment with vehicle (Figures 5B and
W1). The average tumor volumes on day 21 after inoculation were
1800 and 1950 mm3 (P = .67) for the vehicle and AMG 102 treatment
groups, respectively. Thus, the DY5 version of the de2-7 EGFR also
causes profound resistance to AMG102, suggesting that an active kinase
but not autophosphorylation is required for the activation of c-Met.
Figure 2. Effect of panitumumab treatment on the phosphorylation of de2-7 EGFR, c-Met, PDGFRβ and Akt. (A) Western blot analysis of
cell lysates from U87MG.Δ2-7 cells treated with 20 μg/ml panitumumab showing its effect on de2-7 EGFR at two major autophosphory-
laton sites, Y1068 and Y1173 (upper panels), and total de2-7 EGFR (lower panels). Cell lysates from untreated cells served as a base-
line control. The faint band seen above the de2-7 EGFR doublet in the lower panels is the wild-type EGFR, which is coexpressed in these
cells. (B) Western blot analysis of cell lysates from U87MG.Δ2-7 cells treated with either 10 μg/ml AMG 102, 20 μg/ml panitumumab, or a
combination of both showing the effect of these treatments on total c-Met (upper panel) or c-Met phosphorylation (lower panel). Cell
lysates from U87MG.Δ2-7 cells treated with an irrelevant antibody served as a negative control, whereas lysates from A549 cells stimu-
lated by HGF were used as a positive control. (C) Bio-Plex analysis of cell lysates from U87MG.Δ2-7 cells treated with either 10 μg/ml AMG
102, 10 μg/ml panitumumab, or a combination of these antibodies to determine their effect on phosphorylation of PDGFRβ. Untreated
U87MG.Δ2-7 and U87MG.DK cell lysates are included for baseline. (D–G) Bio-Plex analysis of cell lysates from U87MG.Δ2-7 (D and F)
and U87MG.DK (E and G) cells treated with either 10 μg/ml AMG 102, 10 μg/ml panitumumab, or a combination of these antibodies to
determine the effect of these treatments on total (F and G) and phosphorylated Akt (D and E).
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Discussion
Cross talk between the EGFR and c-Met in tumor cells was first
reported by Jo et al. [27], who showed that the activation of c-Met in
several transformed cell lines was mediated by the EGFR ligand
transforming growth factor α. This interaction was proposed to be
unidirectional, but at least one recent report has shown that over-
expression of c-Met can also result in the activation of EGFR [28].
A recent phosphoproteomics screen identified c-Met as a phosphory-
lated protein expressed in U87MG.Δ2-7 cells [24]. One difficulty with
this study is that some of the confirmatory Western blot analyses
Figure 3. Treatment of established glioma xenografts with panitumumab and AMG 102. (A) Mice bearing two U87MG xenografts per
mouse were injected i.p. with PBS (n = 7) or 30 μg of AMG 102 (n = 8), twice weekly for 2 weeks once average tumor volumes had
reached 80 mm3. (B) Mice (n = 6) bearing U87MG.Δ2-7 xenografts were injected i.p. as described in (A). (C) Mice (n = 7) bearing
U87MG.wt xenografts were injected i.p. as described in (A). (D) Mice bearing U87MG.Δ2-7 xenografts were injected i.p. with PBS
(n = 6), 30 μg of AMG 102 (n = 6), 1 mg of panitumumab (n = 5), or a combination of both these antibodies (n = 5), twice weekly
for 2 weeks once average tumor volumes had reached 80 mm3. (E) Mice bearing U87MG.Δ2-7 xenografts were injected i.p. with PBS
(n = 7), 100 μg of AMG 102 (n = 7), 1 mg of panitumumab (n = 5), or a combination of both these antibodies (n = 5), twice weekly for
2 weeks once average tumor volumes had reached 90 mm3. Arrows indicate days on which i.p. injections were administered; n =
number of mice per treatment group. Data were expressed as mean tumor volume ± SEM.
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were performed using whole-cell lysates, and because phospho–
c-Met antibodies cross-react with phosphorylated de2-7 EGFR, these
Western blots need to be interpreted with caution (Figure W2). Our
RTK screen shows that the expression of de2-7 EGFR in U87MG gli-
oma cells leads to phosphorylation of c-Met, a result we confirmed by
immunoprecipitation/Western analysis. The absence of c-Met phos-
phorylation in cells expressing a dead kinase version of de2-7 EGFR
demonstrates that the receptor needs to be kinase active. Because incu-
bation of U87MG.Δ2-7 cells with AMG 102 failed to inhibit the phos-
phorylation of c-Met, this activation must be HGF-independent. In
Figure 4. Immunohistochemical analyses of U87MG.Δ2-7 xenografts treated with AMG 102, panitumumab, or a combination of these
antibodies. Micewith established U87MG.Δ2-7 xenografts (120mm3) were treatedwith PBS, 1mg of panitumumab, 30 μg of AMG 102, and
a combination of panitumumab and AMG 102 on days 7 and 10 after inoculation and tumors resected on day 11. Frozen sections from
individual tumors from each treatment group were stained for Ki67 (proliferation marker, A), CD31 (vessel marker, B), and TUNEL (apoptosis
marker, C). The number of cells/vessels staining positive per field of view (original magnification, ×200) was calculated for eachmarker, and
data were expressed as mean number of cells/vessels per field ± SEM, n = number of fields counted.
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contrast, treatment of U87MG.Δ2-7 cells with panitumumab, which
binds and inhibits de2-7 EGFR phosphorylation, ablated the phos-
phorylation of c-Met, further confirming that c-Met activation is me-
diated by de2-7 EGFR.
Phosphorylation of Akt is downstream of both de2-7 EGFR and
c-Met [29,30]. Addition of AMG 102 to U87MG.DK cells reduced
the level of pAkt as expected. Interestingly, pAkt was also reduced by
panitumumab, suggesting that the endogenous wild-type EGFR also
contributes to pAkt in these cells. Expression of de2-7 EGFR in
U87MG cells dramatically enhanced pAkt levels, this increase being
reversible by treatment with panitumumab. In contrast, AMG 102
had virtually no effect on the level of pAkt in U87MG.Δ2-7 cells,
confirming the inability of this HGF-neutralizing antibody to reduce
c-Met–stimulated pAkt in cells expressing de2-7 EGFR. This lack of
in vitro response to AMG 102 was extended to tumor models, where
low-dose AMG 102 had profound antitumor activity against U87MG
and U87MG.wt xenografts but only a minor effect on the growth of
U87MG.Δ2-7 xenografts, even at high doses. In contrast, panitumu-
mab inhibited the growth of U87MG.Δ2-7 xenografts by inducing
apoptosis rapidly after the commencement of treatment, consistent
with the induction of oncogenic shock. Importantly, the combination
of AMG 102 and panitumumab generated greater than additive anti-
tumor activity in U87MG.Δ2-7 xenografts and further increased apop-
tosis, especially in the central core of the tumor. We are currently
screening cells and tumors in an attempt to identify those apoptotic
molecules responsible for this antitumor effect [31]. U87MG.DY5
xenografts, which express a de2-7 EGFRmolecule with an active kinase
but is incapable of autophosphorylation at the five major autophos-
phorylation sites, were also resistant to AMG 102, suggesting that acti-
vation of c-Met by de2-7 EGFR occurs through a direct interaction
rather than through phosphorylated docking sites.
Although it is difficult to detect the low level of phosphorylated c-Met
in parental U87MG cells (phospho–c-Met is detectable upon over-
exposure of Western blots), these cells are addicted to oncogenic signals
generated by the HGF/c-Met autocrine loop as treatment with AMG
102 leads to complete tumor regressions (Figure 3A and [21]). Forced
expression of de2-7 EGFR in these cells seems to shift the oncogene
addiction from this autocrine loop to the de2-7 EGFR. The ease with
which this is achieved probably reflects that de2-7 EGFR and c-Met
activate a number of downstream pathways in common, particularly
pAkt [29,30]. However, despite the long-term expression of de2-7
EGFR, U87MG.Δ2-7 cells can quickly revert to dependence on the
c-Met axis after the antibody-mediated in vivo inhibition of de2-7
EGFR. The addition of AMG 102 to the treatment regimen clearly dis-
rupts this process leading to profound tumor inhibition. The plasticity
of oncogene addiction demonstrated here has significant implications
for targeted therapy. Indeed, our work suggests that some tumor cells
can harbor a hierarchy of activated oncogenes, possibly arising through
their ongoing evolution. Thus, even targeting of the dominant oncogene
in some solid tumors may be relatively ineffective as its inhibition can be
rapidly overcome by the promotion of other activated oncogenes to the
dominant position within the cell. This provides another reason for the
targeting of multiple RTKs or downstream signals to obtain inhibition
of GBM growth.
Interestingly, our screen identified several other RTKs potentially
activated by de2-7 EGFR, including PDGFRβ. Using an immuno-
fluorescence-based bead assay, we were able to confirm the activation
of PDGFRβ by de2-7 EGFR. Thus, our observations may apply to a
range of ligand-based therapeutics. Ligand stimulation of the wild-
type EGFR can also activate PDGFRβ in a ligand-independent manner
by heterodimerization, highlighting that these two classes of receptors
can directly interact [32]. Furthermore, PDGFRβ has been shown to
drive oncogene addiction in glioma models; thus, it would be interest-
ing to determine the contribution of activated PDGFRβ to the tumori-
genicity of de2-7 EGFR [33]. Given the low level of autoactivation seen
in the de2-7 EGFR, this promiscuous activation of other RTKs by this
receptor may explain its significant protumor activity and possibly why
it signals in a qualitatively different manner to the wild-type EGFR
[30,34].We are currently developing phosphorylation assays for EphA7
and fibroblast growth factor receptor 3 to confirm their activation by
Figure 5. Efficacy of AMG 102 treatment on U87MG.DY5 xenografts. (A) Western blot analysis of cell lysates from U87MG.Δ2-7 and
U87MG.DY5 cells showing phosphorylation status at the Y1068 and Y1173 autophosphorylation sites (upper panels), total de2-7 EGFR
or DY5 (middle panels), and α-tubulin as a loading control (lower panels). (B) Mice (n = 6) bearing U87MG.DY5 xenografts were injected
i.p. with PBS or 30 μg of AMG 102 twice weekly for 2 weeks once average tumor volumes had reached 130 mm3. Arrows indicate days
on which i.p. injections were administered; n= number of mice per treatment group. Data were expressed as mean tumor volume ± SEM.
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de2-7 EGFR. Our initial investigations suggest that it may be EphA2
that is activated not EphA7, once again highlighting issues of uncharac-
terized antibody cross-reactivity.
Apart from the specific effects on AMG 102 therapy, the promis-
cuous nature of de2-7 EGFR signaling raises some general questions
with respect to the use of targeted therapies. Firstly, using U87MG-
transfected cells and relevant controls meant we knew that de2-7
EGFR was the dominant kinase and that the c-Met axis would most
likely replace this pathway in U87MG.Δ2-7 xenografts, but identifi-
cation of the dominant kinase without prior knowledge remains
problematical. Secondly, if it is not possible to identify the dominant
activated kinase, can you inhibit tumor growth by targeting several
of the secondary kinases, and if so, how many need to be function-
ally blocked? Satisfying answers to these questions would allow for
personalized therapeutics that may well improve clinical outcome.
Clearly, the ongoing development of targeted therapies needs to be
supported by a rigorous analysis of signaling pathways in cell lines and
clinical samples so that we can develop methodologies for addressing
these questions.
The data presented here will be used to support the initiation of
a clinical trial in GBM patients using the combination of panitumu-
mab and AMG 102. The frequent activation of both signaling cas-
cades in GBM and the ability of de2-7 EGFR, and possibly other
EGFR mutations, to directly activate c-Met clearly justify such a trial.
A variety of EGFR antibodies have been shown to cross the blood-
brain barrier, with some efficacy reported [35]. A phase 2 trial with
AMG 102 in GBM patients produced clinical responses [36], indi-
cating that this antibody also crosses the blood-brain barrier. Given
that bevacizumab, an antibody directed to vascular endothelial growth
factor, has shown antitumor activity in GBM models and patients
[37,38], it would be interesting to see if it enhances the activity of
the panitumumab/AMG 102 combination.
More generally, our observations demonstrate that some tumor
cells may contain a hierarchy of activated oncogenes, thus allowing for
rapid compensation after the inactivation of the dominant oncogene.
The ease by which this occurs raises challenges for targeted therapy ap-
proaches not only for GBM but also for other complex solid tumors.
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Figure W1. Survival data from xenograft studies. Survival analyses for the therapy studies described in Figures 3, A and D, and 5B.
Survival was evaluated using the technique of Kaplan-Meier with comparisons between groups analyzed by log-rank test. A combined
end point of moribund condition or tumor volume reaching 1000 mm3 in mice treated with vehicle.
Figure W2. Cross-reactivity between phospho–c-Met antibodies and constitutively active de2-7 EGFR. (A) U87MG.Δ2-7, U87MG.DK, and
U87MG.DY5 whole-cell lysates were Western blotted with mAb 806 (anti-EGFR; middle panel) or anti–phospho c-Met (upper panel; rabbit
(polyclonal) phosphospecific anti–c-Met [pYpYpY1230/1234/1235] from Invitrogen). De2-7 EGFR–related proteins can be seen in all cell lines. In
contrast, a p–c-Met band can only be seen in U87MG.Δ2-7. Because the de2-7 EGFR is not phosphorylated in U87MG.DK and U87MG.DY5
cells and because p–c-Met and de2-7 EGFR comigrate (lower panel), it is impossible to determine whether the band seen in the upper
panel is p–c-Met or the antibody cross-reacting with de2-7 EGFR. (B) U87MG.Δ2-7 and U87MG.DK cells were immunoprecipitated with
DO24 (c-Met–specific) or DH8.3 (de2-7 EGFR–specific) and Western blotted with phospho–c-Met (upper panel) or mAb 806 (lower panel).
A549 cells ± HGF were used as a control. As can be clearly seen, the de2-7 EGFR immunoprecipitated by DH8.3 cross-reacted with the
anti–p–c-Met antibody. Specific phosphorylation of c-Met could only be observed after immunoprecipitation with DO24. Similar results
were obtained using three different phosphospecific c-Met antibodies. Thus, these antibodies cannot be used to determine levels of phos-
phorylated c-Met by immunohistochemistry in tissues expressing the de2-7 EGFR.
